This website is for US healthcare professionals

close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Filter 686 trials Clear all
Filter by:

A Study to Evaluate the Effect of Juvederm Volift With Lidocaine on Aging Hands in Participants Age 35 and Older

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Skin Depressions, Skin Elasticity, Skin Laxity
    Skin Depressions, Skin Elasticity, Skin Laxity
  • Phase Phase 4
    Phase 4
INTERVENTION

Device: Juvéderm® VOLIFT with Lidocaine

Eligibility
  • Ages: 35 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Device: Juvéderm® VOLIFT with Lidocaine

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Eurofins Pharmascan /ID# 233683, Lyon, France

Brief Summary

This study will evaluate the effect of Juvederm Volift with Lidocaine, an injectable gel implant, to treat aging hands of participants 35 and older.

Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Plaque Psoriasis
    Plaque Psoriasis
  • Phase Phase 4
    Phase 4
INTERVENTION

Drug: Dimethyl fumarate (DMF) standard scheme, Drug: Dimethyl fumarate (DMF) simplified scheme, Drug: Tildrakizumab

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Dimethyl fumarate (DMF) standard scheme, Drug: Dimethyl fumarate (DMF) simplified scheme, Drug: Tildrakizumab

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Investigator Site 3, Augsburg, Germany

Brief Summary

The purpose of this study is to assess the efficacy, safety and tolerability of Tildrakizumab in moderate-to-severe plaque psoriasis participants who are non-responder to Dimethyl fumarate (DMF) at Week 16. The study consists of two parts. Part 1 will include the first 16 weeks of the Treatment Period and Part 2 will include the last 24 weeks of the Treatment Period.

Effects of Switching From Racemic Methadone to R-methadone on QTc Intervals

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Adverse Drug Effect, Drug Effect, Heart Arrhythmia
    Adverse Drug Effect, Drug Effect, Heart Arrhythmia
  • Phase Phase 4
    Phase 4
INTERVENTION

Drug: Same individuals treated with racemic methadone and switched to levomethadone (R-methadone)

Eligibility
  • Ages: 18 to 70 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Same individuals treated with racemic methadone and switched to levomethadone (R-methadone)

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Department of Pharmacology , Oslo University Hospital, Oslo, Norway

Brief Summary

Effects of switching from racemic methadone to R-methadone on serum methadone concentrations and QTc intervals

Performance of Contrast-Enhanced Spectral Mammography to Assess Neoadjuvant Chemotherapy Response (CEDM)

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Breast Cancer
    Breast Cancer
  • Phase Phase 4
    Phase 4
INTERVENTION

Procedure: Digital Mammography, Drug: Low Osmolar Contrast Material, 300-399 Mg/Ml Iodine Concentration, Per Ml

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Procedure: Digital Mammography, Drug: Low Osmolar Contrast Material, 300-399 Mg/Ml Iodine Concentration, Per Ml

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

UT Southwestern Medical Center, Dallas, Texas, United States

Brief Summary

This study is designed to investigate the diagnostic accuracy of Contrast Enhanced Spectral Mammography (CEDM) in predicting early neoadjuvant therapy response and pathologic complete response (pCR) compared to mammography. Patients diagnosed with invasive breast cancer with available mammography and ultrasound imaging are eligible for the study. Eligible patients will be imaged at baseline (before initiation of neoadjuvant chemotherapy or endocrine therapy), early (2-4 cycles of neoadjuvant therapy) and late (after completion of neoadjuvant chemotherapy or endocrine therapy) timepoints with mammography. CEDM will be done within 2 weeks of the specified timepoint. Additionally, a survey of subject experience with CEDM and other pre-operative imaging will be collected after CEDM is performed.

Comparing a Virtual vs. Face to Face Weight Management Program Using Phentermine for Patients With Overweight or Obesity

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Obesity
    Obesity
  • Phase Phase 4
    Phase 4
INTERVENTION

Drug: Phentermine 37.5 Mg, Behavioral: Dietary program, Behavioral: Exercise program

Eligibility
  • Ages: 18 to 65 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Phentermine 37.5 Mg, Behavioral: Dietary program, Behavioral: Exercise program

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Cleveland Clinic, Cleveland, Ohio, United States

Brief Summary

This study will study the effects associated with the prescription of phentermine in a virtual setting, comparing with prescription of phentermine via a standard face-to-face visit for patients with obesity or overweight.

Evaluation of the Safety and Immunogenicity of Hepatitis A Vaccine

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Vaccination
    Vaccination
  • Phase Phase 4
    Phase 4
INTERVENTION

Biological: Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang, Biological: Hepatitis A (Live) Vaccine, Freeze-dried produced by the Institute of Medical Biology, CAMS, Biological: Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun

Eligibility
  • Ages: 18 to 24 Months (Child)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Biological: Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang, Biological: Hepatitis A (Live) Vaccine, Freeze-dried produced by the Institute of Medical Biology, CAMS, Biological: Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Yangxian Center for Disease Control and Prevention, Hanzhong, Shaanxi, China

Brief Summary

Subjects will be recruited and divided into 3 groups: 1. Hepatitis A(Live)Vaccine,Freeze-dried produced by Changchun Institute of Biological Products Co., Ltd 2. Hepatitis A(Live)Vaccine,Freeze-dried produced by Zhejiang Pukang Biotechnology Co., Ltd., and 3. Hepatitis A(Live)Vaccine,Freeze-dried produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. After immunization, the immunogenicity and safety of three different manufacturers will be compared and the data will be analyzed.

Randomized Placebo-controlled Trial of Hydroxychloroquine in Outpatient Cases With Coronavirus Disease 2019 (COVID-19)

  • Status Active, not recruiting
    Active, not recruiting
  • Condition COVID-19
    COVID-19
  • Phase Phase 4
    Phase 4
INTERVENTION

Drug: Hydroxychloroquine, Drug: Placebo

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Hydroxychloroquine, Drug: Placebo

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Hospital São Camilo Pompéia, São Paulo, Brazil

Brief Summary

In December 2019, a group of patients with pneumonia of unknown cause was identified in Wuhan, in the Hubei province, China. Despite the need of target specific therapeutic options for COVID-19, until now there is no proof of effectiveness of any specific intervention. Some limited observational trials and also evidence from randomized trials have shown no benefit of hydroxychloroquine in inpatient context. Thus, studies evaluating interventions in an outpatient setting in non-severe patients can provide important information related to prognosis and safety. In this way, the present study will evaluate the effectiveness and safety of the use of hydroxychloroquine in COVID-19 outpatients by means of a Randomized, double-blind, placebo-controlled trial

Reducing COVID-19 Related Hospital Admission in Elderly by BCG Vaccination

  • Status Active, not recruiting
    Active, not recruiting
  • Condition COVID-19
    COVID-19
  • Phase Phase 4
    Phase 4
INTERVENTION

Biological: BCG vaccine, Biological: Placebo

Eligibility
  • Ages: 60 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Biological: BCG vaccine, Biological: Placebo

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Radboud University, Nijmegen, Gelderland, Netherlands

Brief Summary

Bacillus Calmette-Guérin (BCG) vaccine not only protects against tuberculosis, but has also been shown to induce protection against various infections with a viral aetiology, leading to significant reductions in morbidity and mortality. We hypothesize that BCG vaccination might be a potent preventive measure against SARS-CoV-2 infection and/or may reduce disease severity in elderly people, who are known to be at increased risk of illness and death from SARS-CoV-2 infection. Therefore, we will in this placebo-controlled adaptive multi-centre randomized controlled trial evaluate the ability of BCG to reduce hospital admission and its efficacy to improve the clinical course of SARS-CoV-2 infection in elderly people((≥ 60 years of age).

DHFS for Medication Adherence Support During Hospital Admissions for Person Living With HIV

  • Status Active, not recruiting
    Active, not recruiting
  • Condition HIV/AIDS
    HIV/AIDS
  • Phase Phase 4
    Phase 4
INTERVENTION

Device: Digital Health Feedback System(DHFS)

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Device: Digital Health Feedback System(DHFS)

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

UCSD AntiViral Research Center, San Diego, California, United States

Brief Summary

This study is a prospective single arm open label intervention study over 16 weeks using the DHFS and a telemedicine platform with persons living with HIV who are not virologically suppressed, admitted to UCSD Hillcrest Medical Center and initiating or restarting anti-retroviral therapy (ARVs). This proof of concept study will investigate the feasibility of using the DHFS in hospitalized individuals living with HIV to support ARV adherence. The Study intervention has an initiation phase of 2 weeks, a persistence phase of 14 weeks and a follow-up phase out to 48 weeks. Once study consent is obtained, the participant will receive a focused case navigation, psychiatric and substance abuse evaluation and will initiate digitized ARVs, either in hospital or at the AVRC within 14 days of hospital discharge, in collaboration with their providers. The study intervention will be considered to start from the point at which the DHFS is started. The study team will ensure the participants continue to utilize the DHFS both in hospital and after discharge. Following the 16 week intervention the study team will continue to follow participants to evaluate retention in care and viral suppression up to 48 weeks in collaboration with the outpatient care providers.

Reward Sensitivity and Pharmacotherapy for Smoking Cessation

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Tobacco Use Cessation
    Tobacco Use Cessation
  • Phase Phase 4
    Phase 4
INTERVENTION

Drug: Varenicline, Drug: Nicotine Patch, Drug: Placebo Patch, Drug: Placebo Tablet, Behavioral: Questionnaires, Behavioral: Counseling Sessions, Other: Lab Session, Other: Saliva Test

Eligibility
  • Ages: 18 to 75 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Drug: Varenicline, Drug: Nicotine Patch, Drug: Placebo Patch, Drug: Placebo Tablet, Behavioral: Questionnaires, Behavioral: Counseling Sessions, Other: Lab Session, Other: Saliva Test

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Brief Summary

The goal of this clinical research study is learn if varenicline or the nicotine patch can help people with different types of emotion and attention levels to quit smoking.